Unknown

Dataset Information

0

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.


ABSTRACT: Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CAR-T19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti-CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.

SUBMITTER: Blanco B 

PROVIDER: S-EPMC7612571 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Blanco Belén B   Ramírez-Fernández Ángel Á   Bueno Clara C   Argemí-Muntadas Lidia L   Fuentes Patricia P   Aguilar-Sopeña Óscar Ó   Gutierrez-Agüera Francisco F   Zanetti Samanta Romina SR   Tapia-Galisteo Antonio A   Díez-Alonso Laura L   Segura-Tudela Alejandro A   Castellà Maria M   Marzal Berta B   Betriu Sergi S   Harwood Seandean L SL   Compte Marta M   Lykkemark Simon S   Erce-Llamazares Ainhoa A   Rubio-Pérez Laura L   Jiménez-Reinoso Anaïs A   Domínguez-Alonso Carmen C   Neves Maria M   Morales Pablo P   Paz-Artal Estela E   Guedan Sonia S   Sanz Laura L   Toribio María L ML   Roda-Navarro Pedro P   Juan Manel M   Menéndez Pablo P   Álvarez-Vallina Luis L  

Cancer immunology research 20220401 4


Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CAR  ...[more]

Similar Datasets

| S-EPMC9953531 | biostudies-literature
| S-EPMC12669218 | biostudies-literature
| S-EPMC9979750 | biostudies-literature
| S-EPMC8179843 | biostudies-literature
| S-EPMC9647791 | biostudies-literature
| S-EPMC6354733 | biostudies-literature